SelectImmune Pharma announces new patent granted for IRF7 inhibitors case
SelectImmune Pharma AB is pleased to announce the Decision to Grant on the European IRF7 Inhibitors case by the European Patent Office (EPO).The patent application, EP3277813, relates to IRF7 inhibitors for use in treating bacterial infections. IRF7 inhibitors are a new way of regulating inflammation and resistance to infection. The European Patent Office (EPO) has granted the patent application as of September 16th, 2020 for 38 European countries. Specific genes regulate innate immune responses to bacterial infection and the outcome of genetic variation can be beneficial or destructive,